Liu et al. found that KRAS/SMARCA4 co-mutated patients had significantly lower activated Cluster of Differentiation (CD4+) memory T cells (p = 0.0035) and (CD8+) T-cells proportions (p = 0.015) than KRAS-mutated/SMARCA4 wild-type NSCLC patients [25]. The gene discussed is SMARCA4; the disease is non-small cell lung carcinoma.